NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE109635 Query DataSets for GSE109635
Status Public on Jan 30, 2022
Title In human CD16+ monocytes NK1R signaling upregulates inflammatory pathways and negatively regulates apoptosis
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary The neurokinin-1 receptor (NK1R) pathway has immunomodulatory properties and is implicated in the pathophysiology of neurodegenerative, infectious and inflammatory diseases. Monocytes are important cells in inflammation and they consist of subsets with distinct phenotypes and biological functions. NK1R signaling is elevated in conditions that alter the balance of monocyte subsets, such as in HIV infection. In order to understand the pro-inflammatory mechanism of NK1R signaling in monocyte subsets, a transcriptome study was performed using RNA sequencing. Human primary peripheral monocytes were treated with the NK1R cognate ligand, substance P (SP), prior to being sorted into CD16- and CD16+ subsets. SP treatment led to the differential expression of 38 genes in CD16- monocytes and 12 genes in CD16+ monocytes. The canonical NF-κB pathway was activated in both subsets, as indicated by the upregulation of transcripts including IL1α, IL1β, IL6, CCL3 and CCL4. In the CD16+ monocytes, NK1R signaling led to priming of the NLRP3 inflammasome and upregulated transcripts including NLRP3 and CARD16. Alternative splicing analysis showed that NK1R signaling resulted in differential exon usage of CASP1 and CARD16 in CD16+ monocytes. SP treatment altered the properties of both CD16- and CD16+ monocytes, leading to an inflammatory response with activation of the canonical NF-κB pathway in both monocyte subsets, and priming of the NLRP3 inflammasome in the CD16+ subset.
 
Overall design mRNA transcript analysis of primary human CD16- and CD16+ monocyte subsets under no treatment conditions (3 replicates), SP treatment (2 replicates) or treatment with vehicle control (2 replicates) using the Illumina HiSeq 4000 Sequencing System

mRNA transcript analysis of primary human CD16- and CD16+ monocyte subsets under SP treatment (6 replicates) or treatment with vehicle control (6 replicates) using the Illumina NovaSeq 6000 Sequencing System
 
Contributor(s) Pappa V, Spitsin S, Douglas SD, Gaskill PJ
Citation(s) 33640716
Submission date Jan 25, 2018
Last update date Feb 01, 2022
Contact name Steven D Douglas
E-mail(s) DOUGLAS@EMAIL.CHOP.EDU
Phone 267-426-9570
Organization name The Children's Hospital of Philadelphia
Department Pediatrics
Lab Abramson Research Building 1204
Street address 3615 Civic Center Blvd
City Philadelphia
State/province PA
ZIP/Postal code 19104
Country USA
 
Platforms (2)
GPL20301 Illumina HiSeq 4000 (Homo sapiens)
GPL24676 Illumina NovaSeq 6000 (Homo sapiens)
Samples (38)
GSM2947722 untreated CD16- monocytes - replicate 1
GSM2947723 untreated CD16+ monocytes - replicate 1
GSM2947724 untreated CD16- monocytes - replicate 2
Relations
BioProject PRJNA431570
SRA SRP131231

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE109635_RAW.tar 7.0 Mb (http)(custom) TAR (of TXT)
SRA Run SelectorHelp
Raw data are available in SRA
Processed data provided as supplementary file
| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap